Futureproofing AAV Processes: Viral Safety Considerations In Process Development

AAV manufacturing requires a viral safety strategy suited to the realities of vector production. Classical virus clearance methods may offer limited applicability, while higher vector doses can increase manufacturing demands and potential risk. An integrated approach can help address these challenges from early process development through commercial readiness. Cell culture media virus filtration provides a proactive barrier against adventitious contaminants upstream, while high-resolution anion exchange chromatography strengthens downstream viral safety. When designed together, these complementary strategies support intentional viral risk management across the AAV process. Embedding viral safety considerations early can also reduce later-stage challenges, support regulatory expectations, and create a stronger foundation for reliable GMP production.

Explore how filtration and chromatography can work together to advance safer, scalable AAV manufacturing.